SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52153 679 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
51928Madrigal will probably get FDA approval on its NASH drug before competitors likeArt Bechhoefer-2/1/2022
51927I have maintained an interest in FibroGen for several years. I have attended viArt Bechhoefer32/1/2022
51926Thanks. No position for me either. I've been burned by NASH with both GenfiA.J. Mullen-2/1/2022
51925." FibroGen recently expanded its research and development portfolio to incLance Bredvold-2/1/2022
51924There’s a lot of skepticism that anything will work in NASH, and MDGL didn’t helDewDiligence_on_SI-2/1/2022
51923Thanks. I had read that, but didn't dwell on the distinction between a presuA.J. Mullen-1/31/2022
51922MDGL's phase-3 release today was for the NAFLD ("presumed NASH") tDewDiligence_on_SI-1/31/2022
51921Madrigal, MDGL, released encouraging data from their big Phase III NASH study toA.J. Mullen-1/31/2022
51920youtube.comAloner-1/31/2022
51919[graphic]kingfisher-1/31/2022
51918PRVB's share-price moves are an indication of how weak the current biotech mDewDiligence_on_SI-1/28/2022
51917PRVB is UP 20% after hours on a re-submission announcement. A glimmer of hope inAloner-1/27/2022
51916Is CRISPR Therapeutics a Buy?If you're willing to speculate, yes. [graphic]Frank Sully-1/26/2022
51915The FDA has lifted its hold on Mind Medical's Phase IIb trial, using a tweakA.J. Mullen-1/25/2022
51914Time will tell of course. Measured by one day, I'm pretty happy. This isnJamesK-1/24/2022
51913I agree with your view that development stage biotech stocks seem oversold, but Art Bechhoefer11/24/2022
51912I agree with your reasoning, if not your choice of metaphor, and hope you are riA.J. Mullen-1/24/2022
51911Throwing in the towel and I'm buying. Going in the water. Been sitting out bJamesK-1/24/2022
51910Am I correct in assuming that valuation modelers should expect asset values to gArt Bechhoefer21/19/2022
51909I commented on the interest-rate effect in: twitter.com Valuation modelers are DewDiligence_on_SI-1/19/2022
51908There has been a gradual decline in prices of numerous small and medium size bioArt Bechhoefer11/19/2022
51907XBI down to mid 90's. Wonder if the 2020 crash lows are out of the question.JamesK-1/18/2022
51906Trying to find real kn95 and/or n95 masks? Here’s a summary of my adventure: 1software salesperson-1/15/2022
51905Sorry to hear you were a victim Dew. You advised me a last June that PRTA (ProtLance Bredvold-1/12/2022
51904For all practical purposes, in an indoor public environment one should assume thDewDiligence_on_SI31/11/2022
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News